SUN-370 TOLVAPTAN USE IN YOUNG ADULTS WITH RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

Regulatory approval of tolvaptan as a treatment for autosomal dominant polycystic kidney disease (ADPKD) in adults with evidence of rapidly progressing disease has changed the management of this condition. Given that young adults with ADPKD are likely to have early-stage disease and that questions on the screening, assessment, and treatment of these patients remain debated, a manuscript on tolvaptan use in the 18−24-year age group is needed. The phase 3 Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO 3:4) clinical trial evaluated tolvaptan in a large population (N=1,445) of subjects aged 18−50 years over a 3-year period.